These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 11360243)

  • 21. Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus.
    Kato N; Sekiya H; Ootsuyama Y; Nakazawa T; Hijikata M; Ohkoshi S; Shimotohno K
    J Virol; 1993 Jul; 67(7):3923-30. PubMed ID: 7685404
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibodies directed to envelope proteins of hepatitis C virus outside of hypervariable region 1.
    Lechner S; Rispeter K; Meisel H; Kraas W; Jung G; Roggendorf M; Zibert A
    Virology; 1998 Apr; 243(2):313-21. PubMed ID: 9568031
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acceleration of hepatitis C virus envelope evolution in humans is consistent with progressive humoral immune selection during the transition from acute to chronic infection.
    Liu L; Fisher BE; Dowd KA; Astemborski J; Cox AL; Ray SC
    J Virol; 2010 May; 84(10):5067-77. PubMed ID: 20200239
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Experimental vaccine activities of recombinant E1 and E2 glycoproteins and hypervariable region 1 peptides of hepatitis C virus in chimpanzees.
    Esumi M; Rikihisa T; Nishimura S; Goto J; Mizuno K; Zhou YH; Shikata T
    Arch Virol; 1999; 144(5):973-80. PubMed ID: 10416378
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypervariable region 1 of hepatitis C virus: immunological decoy or biologically relevant domain?
    Mondelli MU; Cerino A; Segagni L; Meola A; Cividini A; Silini E; Nicosia A
    Antiviral Res; 2001 Nov; 52(2):153-9. PubMed ID: 11672825
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reactivity of synthetic peptides representing selected sections of hepatitis C virus core and envelope proteins with a panel of hepatitis C virus-seropositive human plasma.
    Jackson P; Petrik J; Alexander GJ; Pearson G; Allain JP
    J Med Virol; 1997 Jan; 51(1):67-79. PubMed ID: 8986952
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vivo and in vitro evidence that cross-reactive antibodies to C-terminus of hypervariable region 1 do not neutralize heterologous hepatitis C virus.
    Esumi M; Zhou YH; Tanoue T; Tomoguri T; Hayasaka I
    Vaccine; 2002 Aug; 20(25-26):3095-103. PubMed ID: 12163260
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Antibody responses to consensus sequence of hypervariable region 1 from hepatitis C virus protein E2 in relation to the phase of infection].
    Nikolaeva LI; Finogenova MP; Shibnev VA
    Vopr Virusol; 2006; 51(4):16-9. PubMed ID: 16929593
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypervariable region diversity of hepatitis C virus and humoral response: comparison between patients with or without cirrhosis.
    Allain JP; Zhai W; Shang D; Timmers E; Alexander GJ
    J Med Virol; 1999 Sep; 59(1):25-31. PubMed ID: 10440804
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sequence evolution of the hypervariable region in the putative envelope region E2/NS1 of hepatitis C virus is correlated with specific humoral immune responses.
    van Doorn LJ; Capriles I; Maertens G; DeLeys R; Murray K; Kos T; Schellekens H; Quint W
    J Virol; 1995 Feb; 69(2):773-8. PubMed ID: 7815542
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic drift in hypervariable region 1 of the viral genome in persistent hepatitis C virus infection.
    Kato N; Ootsuyama Y; Sekiya H; Ohkoshi S; Nakazawa T; Hijikata M; Shimotohno K
    J Virol; 1994 Aug; 68(8):4776-84. PubMed ID: 7518526
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Complement-mediated enhancement of antibody function for neutralization of pseudotype virus containing hepatitis C virus E2 chimeric glycoprotein.
    Meyer K; Basu A; Przysiecki CT; Lagging LM; Di Bisceglie AM; Conley AJ; Ray R
    J Virol; 2002 Mar; 76(5):2150-8. PubMed ID: 11836392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The serology of hepatitis C virus (HCV) infection: antibody crossreaction in the hypervariable region 1.
    da Silva Cardoso M; Siemoneit K; Nemecek V; Epple S; Koerner K; Kubanek B
    Arch Virol; 1995; 140(10):1705-13. PubMed ID: 7503672
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A possible role of hypervariable region 1 quasispecies in escape of hepatitis C virus particles from neutralization.
    Korenaga M; Hino K; Katoh Y; Yamaguchi Y; Okuda M; Yoshioka K; Okita K
    J Viral Hepat; 2001 Sep; 8(5):331-40. PubMed ID: 11555190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evolutionary study of hepatitis C virus envelope genes during primary infection.
    Chen S; Wang YM
    Chin Med J (Engl); 2007 Dec; 120(24):2174-80. PubMed ID: 18167197
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predominance of antibodies to hepatitis C virus envelope proteins in various disease statuses of hepatitis C.
    PodurI CD; Khanna A; Khundmiri SJ; Khaja MN; Kumar KS; Sugunan VS; Habibullah CM; Das MR
    Acta Virol; 2001 Feb; 45(1):1-6. PubMed ID: 11394572
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The hypervariable region 1 protein of hepatitis C virus broadly reactive with sera of patients with chronic hepatitis C has a similar amino acid sequence with the consensus sequence.
    Watanabe K; Yoshioka K; Ito H; Ishigami M; Takagi K; Utsunomiya S; Kobayashi M; Kishimoto H; Yano M; Kakumu S
    Virology; 1999 Nov; 264(1):153-8. PubMed ID: 10544140
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibody Response to Hypervariable Region 1 Interferes with Broadly Neutralizing Antibodies to Hepatitis C Virus.
    Keck ZY; Girard-Blanc C; Wang W; Lau P; Zuiani A; Rey FA; Krey T; Diamond MS; Foung SK
    J Virol; 2016 Jan; 90(6):3112-22. PubMed ID: 26739044
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evolutionary rate and genetic drift of hepatitis C virus are not correlated with the host immune response: studies of infected donor-recipient clusters.
    Allain JP; Dong Y; Vandamme AM; Moulton V; Salemi M
    J Virol; 2000 Mar; 74(6):2541-9. PubMed ID: 10684268
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Humoral immune system targets clonotypic antibody-associated hepatitis C virus.
    Naik AS; Palmer BA; Crosbie O; Kenny-Walsh E; Fanning LJ
    J Gen Virol; 2017 Feb; 98(2):179-189. PubMed ID: 28284234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.